Coding for Immunization Against Respiratory Syncytial Virus

In anticipation of US Food and Drug Administration (FDA) approval of nirsevimab (single-dose monoclonal antibody for seasonal immunization against respiratory syncytial virus [RSV]), codes 90380–90381 were approved by the American Medical Association Current Procedural Terminology® Editorial Panel in May 2023 and released on June 30, 2023. The codes will became effective immediately on FDA approval of the vaccine. There are several things to know about coding for provision and administration of nirsevimab, including the following: Differentiating codes for nirsevimab and palivizumab The appropriate administration code for monoclonal antibody immunization Reporting nirsevimab administration and other services on the same date